• Guided Therapeutics posted net loss attributable to common stockholders of $1.01 million for three months ended March 31, 2026, widening from $462,742 a year earlier.
• General and administrative expense climbed 69% to $450,673, driven by higher attorney’s fees tied to an uplisting to Canadian stock exchange, stock option expense, rent and utilities, payroll, and professional services.
• Research and development expense fell 40% to $44,511, while sales and marketing expense dropped 69% to $22,500.
• Results included a $217,062 gain on remeasurement of deferred compensation conversion liability, inducement charges of $77,593 tied to warrants issued in debt conversions, and interest expense of $150,831.
• Revenue was unchanged at no revenue; management cited expected potential sales of about $1 million over next 12 months, with plans to file clinical results with FDA in second quarter of 2026 and targeting possible China NMPA approval in third or fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guided Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-003195), on May 15, 2026, and is solely responsible for the information contained therein.